Capricor Therapeutics (NASDAQ: CAPR) reported Q4 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $10.6 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.